Eli Lilly opens a new legal front in its battle against compounded GLP-1s

Taking stock of the drug industry, from the lab to the medicine chest

April 23, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Scott Olson/Getty Images STAT+ | Eli Lilly opens a new legal front in its battle against compounded GLP-1s Eli Lilly sued four telehealth firms and their affiliates, but it is adopting a new legal strategy in its fight against compounded GLP-1s. By Ed Silverman and Katie Palmer STAT+ | Bristol's Cobenfy disappoints as supplemental antipsychotic drug The new schizophrenia drug didn't provide additional benefits when given on top of standard-of-care therapy, Bristol Myers Squibb announced Tuesday. By Jason Mast Opinion: Government word search is killing my cutting-edge research Many of my colleagues and their work are falling victim to a nationwide, indiscriminate destruction of university-based biomedical research. By John Quackenbush

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser